Bing Xia
Hangzhou Cancer Hospital · First People's Hospital of Hangzhou
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bing Xia as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:15 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07875465 · Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver MetastasesBing Xia · not yet recruiting · Liver Metastases, Non-Small Cell Lung Cancer, Colorectal Cancer (Diagnosis) · principal investigator
- Early Ph1NCT06224738 · Human HER2-targeted Macrophages Therapy for HER2-positive Advanced Gastric Cancer With Peritoneal MetastasesFirst People's Hospital of Hangzhou · unknown · Gastric Cancer · principal investigator
- Ph2NCT05520853 · SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLCFirst People's Hospital of Hangzhou · unknown · Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:15 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- 27 citationsRCR 5.4
- Is involved-field radiotherapy based on CT safe for patients with limited-stage small-cell lung cancer?Radiother Oncol · 201221 citationsRCR 0.6
- Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.BMC Cancer · 202111 citationsRCR 0.6
- Phase I/II Study of Tifcemalimab, an Anti-B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer.Clin Cancer Res · 20258 citationsRCR 1.8
- 1 citationsRCR 0.2